MYCure focuses on the most frequently diagnosed and deadliest neoplasms worldwide: NSCLC, PDAC and CRC. A potent new therapy against these diseases, like the one proposed in this project, would have a very notable effect. In fact, the MYCure project could change the paradigm of cancer treatment, as it will unveil new interventional strategies for the treatment of these underserved cancer patients, and will address one of the main goals in oncology: to achieve durable responses to treatment. In this context, Peptomyc proposes a revolutionary approach: to attack Myc, an essential function conserved in the majority of tumours. With MYCure, OMO-103 will provide a safer and more effective therapeutic option for NSCLC, PDAC and CRC cancer patients that will significantly increase their life expectancy and quality of life.
The OMO-103 CT consisting of a combined Phase I/II study was approved in March 2021. The Phase I CT has demonstrated the excellent safety of OMO-103 in solid tumour patients and positive signs of efficacy, thus reaching a major de-risking milestone and making OMO-103 really attractive to large pharmaceutical companies. As OMO-103 is expected to treat previously untreatable cancer subtypes, and can be used either as standalone therapy or/and as combination with other current drugs, it will open new market opportunities and significantly expand the market share. This means that the pharmaceutical company commercializing OMO-103 will position itself in a new market, generating a treatment segment that will eventually expand to reach the majority of such cancer patients. Moreover, it is also expected that OMO-103 could eventually treat many more cancer types, further expanding its market opportunities. As such, OMO-103 is poised to generate a real new market in oncology and lends itself to empowering pharma companies in market leadership.
